MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gouédard, C.
Right arrow Articles by Morel, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gouédard, C.
Right arrow Articles by Morel, Y.

Vol. 63, Issue 4, 945-956, April 2003

Opposite Regulation of the Human Paraoxonase-1 Gene PON-1 by Fenofibrate and Statins

Cédric Gouédard, Nadine Koum-Besson, Robert Barouki, and Yannick Morel

Institut National de la Santé et de la Recherche Médicale Unité-490, Centre Universitaire des Saints-Pères, Paris, France (C.G., R.B., Y.M.); Centre d'études du Bouchet, Vert-le Petit, France (N.K.B., Y.M.)

The human paraoxonase-1 (PON-1) is a serum high-density lipoprotein-associated phosphotriesterase secreted mainly by the liver. This enzyme is able to hydrolyze toxic organophosphate xenobiotics, endogenous oxidized phospholipids, and homocysteine thiolactone. Physiologically, it is thought to protect against cardiovascular diseases. The level of PON-1 gene expression is a major determinant of paraoxonase-1 status but little is known regarding the regulation of this gene. We identified several transcription start sites and characterized the regulation of its promoter by fibrates and statins. In HuH7 human hepatoma cells, the PON-1 secreted enzymatic activity and mRNA levels were increased by fenofibric acid (approximately 70%) and decreased by several statins (approximately 50%). Transient and stable transfection assays in HuH7 cells indicated that the modulation of the mRNA and enzymatic activity levels could be accounted for by the regulation of the PON-1 gene promoter activity by these drugs. These effects are probably not mediated by the PPARalpha because over-expression of this receptor decreased the fibrate effect and did not modify statins activity. The repressive effect of statins is reversed by mevalonate and 22(R)-hydroxycholesterol, suggesting the involvement of the liver X receptor in the mechanism. The opposite effects of fenofibrate and statins could be consistent with clinical data on homocysteine levels after hypolipidemic drug treatment. Regarding the toxicological aspects, the induction achieved with fenofibric acid, although limited, could increase organophosphate metabolism and may be relevant in certain conditions for protective treatments.

Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
H. Zhou, K. C. Tan, S. W. Shiu, and Y. Wong
Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy
Nephrol. Dial. Transplant., March 1, 2008; 23(3): 927 - 933.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
B. J. Van Lenten, S. T. Reddy, M. Navab, and A. M. Fogelman
Understanding changes in high density lipoproteins during the acute phase response.
Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1687 - 1688.
[Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
C. Y. Han, T. Chiba, J. S. Campbell, N. Fausto, M. Chaisson, G. Orasanu, J. Plutzky, and A. Chait
Reciprocal and Coordinate Regulation of Serum Amyloid A Versus Apolipoprotein A-I and Paraoxonase-1 by Inflammation in Murine Hepatocytes
Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1806 - 1813.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
D. M. Shih, H. R. Kast-Woelbern, J. Wong, Y.-R. Xia, P. A. Edwards, and A. J. Lusis
A role for FXR and human FGF-19 in the repression of paraoxonase-1 gene expression by bile acids
J. Lipid Res., February 1, 2006; 47(2): 384 - 392.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
C. Gouedard, R. Barouki, and Y. Morel
Induction of the Paraoxonase-1 Gene Expression by Resveratrol
Arterioscler. Thromb. Vasc. Biol., December 1, 2004; 24(12): 2378 - 2383.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
D. J. Hoivik, C. W. Qualls Jr, R. C. Mirabile, N. F. Cariello, C. L. Kimbrough, H. M. Colton, S. P. Anderson, M. J. Santostefano, R. J. O. Morgan, R. R. Dahl, et al.
Fibrates induce hepatic peroxisome and mitochondrial proliferation without overt evidence of cellular proliferation and oxidative stress in cynomolgus monkeys
Carcinogenesis, September 1, 2004; 25(9): 1757 - 1769.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
C. Gouedard, R. Barouki, and Y. Morel
Dietary Polyphenols Increase Paraoxonase 1 Gene Expression by an Aryl Hydrocarbon Receptor-Dependent Mechanism
Mol. Cell. Biol., June 15, 2004; 24(12): 5209 - 5222.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
S. Deakin, I. Leviev, S. Guernier, and R. W. James
Simvastatin Modulates Expression of the PON1 Gene and Increases Serum Paraoxonase: A Role for Sterol Regulatory Element-Binding Protein-2
Arterioscler. Thromb. Vasc. Biol., November 1, 2003; 23(11): 2083 - 2089.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics